#United States #Stockholm #Autoimmune Anemia #nipocalimab #IMAAVY

Promising Results from Johnson & Johnson's IMAAVY® in Treating Warm Autoimmune Hemolytic Anemia

In a landmark study presented by Johnson & Johnson at the EHA 2026 Congress, IMAAVY® (nipocalimab-aahu) has demonstrated promising results for patients suffering from Warm Autoimmune Hemolytic Anemia (wAIHA) — a condition notoriously lacking FDA-approved treatments.

The findings, derived from the pivotal Phase 2/3 ENERGY study, reveal that patients treated with IMAAVY at a dosage of 30 mg/kg exhibited a statistically significant and durable hemoglobin response with rapid effects noted as early as Week 1. This marks a substantial breakthrough for individuals battling a condition characterized by the destruction of red blood cells due to autoantibodies.

Key Findings of the ENERGY Study

The ENERGY study was designed to comprehend the effectiveness of IMAAVY compared to a placebo, focusing on achieving durable hemoglobin improvement, defined as:

• - An increase from baseline in hemoglobin levels of ≥2 g/dL
• - Hemoglobin concentration of ≥10 g/dL
• - Sustained improvements measured over three visits across at least 28 days, beginning post-defined treatment periods
• - Absence of rescue therapy or adjustments made to concurrent medications for treating wAIHA.

Results from the IMAAVY treatment group illuminated a mean increase of at least 1 g/dL in hemoglobin levels at the one-week mark, compared to no significant changes in the placebo cohort. Remarkably, nearly two-thirds of patients attained critical targets by Week 24, emphasizing the potential of this intervention.

Moreover, IMAAVY administration correlated with improvements in fatigue and a reduced reliance on corticosteroids, with noticeable changes in reported fatigue levels as early as Week 2 and maintained throughout the 24-week treatment duration. These enhancements are invaluable to patients who suffer from debilitating fatigue associated with wAIHA.

Safety Profile and Future Implications

The safety profile of IMAAVY was consistent with established parameters, with the most frequently observed side effects including peripheral edema, diarrhea, and fever, affecting over 10% of treated individuals. Notably, the study reported no new safety signals, reinforcing IMAAVY's viability as a treatment option.

Dr. Bruno Fattizzo, Assistant Professor at the University of Milan and a principal investigator in the study, acknowledged the significance of these results, remarking that the rapid onset of effects is critical for clinical practice. He emphasized the importance of addressing the underlying autoantibody-mediated processes that lead to red blood cell destruction in wAIHA.

Dr. Leonard L. Dragone, another leading authority from Johnson & Johnson, outlines the immunoselective nature of IMAAVY, which targets the autoantibodies responsible for disease without compromising essential immune functions. This innovative approach offers hope to a population often reliant on unapproved therapies and broad immunosuppressants.

As part of its regulatory journey, IMAAVY has received U.S. FDA Priority Review status, indicating the urgency and potential of this therapy in meeting previously unmet medical needs for patients suffering from wAIHA.

Conclusion

The advancements showcased in the ENERGY study signal a pivotal moment for wAIHA patients, potentially revolutionizing the treatment landscape for a condition that has severely impacted the lives of many. As the medical community anticipates further developments following these compelling results, IMAAVY stands out as a beacon of hope for those affected by warm autoimmune hemolytic anemia.